Navigation Links
MultiVu Video Feed: Geron Receives FDA Clearance to Begin World's First Human Clinical Trial of Embryonic Stem Cell-Based Therapy
Date:1/23/2009

Geron to Study GRNOPC1 in Patients with Acute Spinal Cord Injury

Geron Corporation (Nasdaq: GERN) announced that the U.S. Food and Drug Administration (FDA) has granted clearance of the company's Investigational New Drug (IND) application for the clinical trial of GRNOPC1 in patients with acute spinal cord injury. The clearance enables Geron to move forward with the world's first study of a human embryonic stem (hESC) cell-based therapy in man.

Geron plans to initiate a Phase I multicenter trial that is designed to establish the safety of GRNOPC1 in patients with "complete" American Spinal Cord Injury Association (ASIA) Grade A subacute thoracic spinal cord injuries. Patients eligible for the Phase I trial must have documented evidence of functionally complete spinal cord injury with a neurological level of T3 to T10 spinal segments and agree to have GRNOPC1 injected into the lesion sites between seven and 14 days after injury.

    For more information about GRNOPC1, please visit:http://www.geron.com

    SATELLITE FEEDS:
    Friday, January 23rd, 2009         Friday, January 23rd, 2009
    9:30 AM - 9:45 AM ET               1:15 PM - 1:30 PM ET
    Galaxy 3C                          Galaxy 3C
    C-Band                             C-Band
    Transponder 8                      Transponder 8
    Downlink Freq. 3860 Vertical       Downlink Freq. 3860 Vertical

Preview and access this video on Pathfire DMG: Slug # 33040

Search within the PR Newswire or MultiVu section by story ID # 33040 or by headline

For technical assistance call Pathfire Customer Care at 1-888-345-0489 or e-mail support@pathfire.com

NEWS: World's First Study of Human Embryonic Stem Cell-Based Therapy In Man

FORMAT: B-roll and Soundbites

ADDITIONAL RESOURCES: Video, contact information and more available at: http://www.prnewswire.com/broadcast/33040/press.html


    SOUNDBITES:
    * Thomas B. Okarma, Ph.D., M.D., President, CEO and Director, Geron
      Corporation

    B-ROLL INCLUDES:
    * spinal cord cell therapy animation
    * lab and manufacturing footage
    * Geron office building exterior shots

VIDEO PROVIDED BY: Geron Corporation

Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations, 1-800-653-5313 EXT. 3


'/>"/>
SOURCE Geron Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. MultiVu Video Feed: U.S Food and Drug Administration (Fda) Approves Latisse(TM) --
2. MultiVu Video Feed: New Rapid Test to Diagnose Flu May Help With Upcoming Flu Season
3. MultiVu Video Feed: Johnson & Johnson Diabetes Institute, LLC Launches New Training Center to Improve Community-Based Diabetes Care
4. MultiVu Video Feed: Easypod(R), Award-Winning Electronic Device
5. MultiVu Video Feed: Hard Rocks 2007 Ambassadors of Rock Tour Is "On the Road Again" With Music Legend Willie Nelson
6. MultiVu Video Feed: Allergan, Inc. Partners With "Project Runway" Designer Kara Saun and Gen Art Fresh Faces In Fashion to Raise Awareness About Excessive Underarm Sweating
7. New Video Streaming Site Created by Ambrose Video Publishing
8. Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes
9. New Online Video Features Brazilian Researcher Elbio Rech
10. Video: 8-Minute Film Documentary Explores Why Humans Age
11. PharmSource President Moderates Videocast on Outsourcing to Asia at AAPS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... ... DuPont Industrial Biosciences (DuPont) and Archer Daniels Midland Company ... Platts Global Energy for their platform technology to produce a revolutionary biobased ... Platts Global Energy Awards, held in New York on Thursday, Dec. 8. , ...
(Date:12/9/2016)... , Dec. 9, 2016 /PRNewswire/ - Portage Biotech Inc. ... PBT.U), is pleased to announce that Biohaven has issued ... New Haven, Connecticut (PRWEB) Dec 9, 2016 ... "Biohaven") announced today that the U.S. Food and Drug ... request covering its drug candidate BHV-0223, an orally dissolving ...
(Date:12/8/2016)... Medical Incorporated ("OncoSec") (NASDAQ: ONCS ), ... announced financial results for the fiscal first quarter ... our commitment to address an unmet medical need ... with the early clinical response data presented from ... on advancing our lead program – ImmunoPulse® IL-12 ...
(Date:12/8/2016)... MOINES, Iowa , Dec. 8, 2016 Eurofins announces ... US Food and President of Eurofins Scientific Inc. (ESI). ... Division with his proven professional and entrepreneurial experience in leading international ... in the US food testing market to uphold Eurofins, status as ... ...
Breaking Biology Technology:
(Date:12/6/2016)... , Dec. 6, 2016 Valencell , the ... it has seen a third consecutive year of triple ... technology in 2016 with a 360 percent increase in ... This increase was driven by sales of its wrist ... interest in its technology for hearables for fitness and ...
(Date:11/30/2016)... and WARSAW, Poland , Nov. 30, 2016 Not many ... of the most crucial aspects of recovery so we need to do it well. ... risks, including heart problems, high blood pressure, stroke, diabetes, and even cancer. ... and find a Christmas present that could help them to manage their sleep quality? ... ...
(Date:11/28/2016)... 28, 2016 "The biometric ... 16.79%" The biometric system market is in the ... the near future. The biometric system market is expected ... at a CAGR of 16.79% between 2016 and 2022. ... biometric technology in smartphones, rising use of biometric technology ...
Breaking Biology News(10 mins):